NuCana PLC (NCNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NuCana PLC (NCNA) has a cash flow conversion efficiency ratio of 0.049x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.28 Million) by net assets ($25.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NuCana PLC - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how NuCana PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NuCana PLC (NCNA) total liabilities for a breakdown of total debt and financial obligations.
NuCana PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NuCana PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zaplox AB
ST:ZAPLOX
|
25.961x |
|
Newpeak Metals Ltd
AU:NPM
|
-0.197x |
|
Mortgage Advice
LSE:MAB1
|
0.179x |
|
The GYM Group PLC
LSE:GYM
|
0.392x |
|
Mega Sun City Holdings Bhd
KLSE:0081
|
-0.010x |
|
Avira Resources Ltd
AU:AVW
|
-0.168x |
|
Frp Advisory Group Plc
LSE:FRP
|
0.275x |
|
LM Funding America Inc
NASDAQ:LMFA
|
-0.063x |
Annual Cash Flow Conversion Efficiency for NuCana PLC (2014–2024)
The table below shows the annual cash flow conversion efficiency of NuCana PLC from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see NCNA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.95 Million | $-19.12 Million | -3.211x | -80.80% |
| 2023-12-31 | $14.89 Million | $-26.44 Million | -1.776x | -195.27% |
| 2022-12-31 | $38.50 Million | $-23.16 Million | -0.601x | -65.49% |
| 2021-12-31 | $65.55 Million | $-23.82 Million | -0.363x | -66.83% |
| 2020-12-31 | $99.23 Million | $-21.62 Million | -0.218x | +41.93% |
| 2019-12-31 | $63.52 Million | $-23.83 Million | -0.375x | -150.44% |
| 2018-12-31 | $81.59 Million | $-12.22 Million | -0.150x | -60.72% |
| 2017-12-31 | $93.42 Million | $-8.71 Million | -0.093x | +74.60% |
| 2016-12-31 | $25.24 Million | $-9.26 Million | -0.367x | -146.16% |
| 2015-12-31 | $29.96 Million | $-4.47 Million | -0.149x | +99.90% |
| 2014-12-31 | $34.51K | $-5.25 Million | -151.998x | -- |
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline in… Read more